Nodus Oncology

Nodus Oncology, founded in 2018 and based in Cambridge, UK, is a private, pre-clinical stage biotech company developing novel cancer therapeutics. Its strategy centers on inducing synthetic lethality and exploiting collateral vulnerabilities in molecularly-defined cancers by targeting DNA repair and replication stress mechanisms. The company's lead assets include a best-in-class PARG inhibitor and a first-in-class DNA replication inhibitor (NOD1i), both aimed at causing cancer cell death through replication catastrophe. Backed by seed funding and strategic partnerships, Nodus is advancing its innovative portfolio towards clinical development.

Platform focused on exploiting genomic instability and replication stress to induce synthetic lethality and collateral vulnerabilities in cancers with specific metabolic weaknesses. It involves inducing DNA gaps and replication stress to trigger cancer cell death via replication catastrophe.

The DDR field is highly competitive, with numerous large pharma and biotech companies developing next-generation PARP and PARG inhibitors. Nodus must differentiate through novel biology, superior compound profiles, or unique biomarker strategies to succeed.